CVE-2022-26239The default privileges for the running service Normand License Manager in Beckman Coulter Remisol Advance v2.0.12.1 and prior allows unprivileged users to overwrite and manipulate executables and lib…
Updated under an hour ago ()
Does this affect you?
It affects beckmancoulter remisol_advance. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.22%, higher than 12% of scored CVEs.
Do this next
Free account, 1 product
The default privileges for the running service Normand License Manager in Beckman Coulter Remisol Advance v2.0.12.1 and prior allows unprivileged users to overwrite and manipulate executables and libraries. This allows attackers to access sensitive data.
- CVSS
- 5.5 MEDIUM (v3.1, NVD)CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N
- Weakness (CWE)
- Not given
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.22% (percentile 12)
- Assigned by
- mitre
- NVD analysis
- Modified
- Record last updated
- Aug 3, 2024
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
beckmancoulter remisol_advance beckmancoulter:remisol_advance | through 2.0.12.1 | NVD |
References
- https://www.beckmancoulter.com/products/clinical-information-management-tools/remisol-advanceproduct
- https://pastebin.com/1QEHrj01third-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.